Study of SGN-30 (Anti-CD30 mAb) in Patients With Primary Cutaneous Anaplastic Large Cell Lymphoma
Status:
Completed
Trial end date:
2007-02-01
Target enrollment:
Participant gender:
Summary
This multi-center, phase II study will be conducted to define the toxicity profile and
antitumor activity of SGN-30 in patients with pcALCL and other closely related
lymphoproliferative disorders.